Entinostat (MS-275)

For research use only. Not for use in humans.

目录号：S1053 别名： SNDX-275

Molecular Weight(MW): 376.41

Entinostat (MS-275)强烈抑制HDAC1和HDAC3，无细胞试验中IC50分别为0.51 μM和1.7 μM，抑制作用强于HDACs 4， 6， 8，和10。Entinostat可诱导自噬和凋亡。Phase 3。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 746.45	现货
5mg	RMB 466.83	现货
10mg	RMB 564.33	现货
25mg	RMB 1233.32	现货
50mg	RMB 2234.07	现货
200mg	RMB 6301.79	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Entinostat (MS-275)发表文献282篇：

Nat Biotechnol, 2020, 10.1038/s41587-019-0388-4

PubMed: 31959954 ( click the link to review the publication )

Cell, 2019, 178(5):1115-1131

PubMed: 31442404 ( click the link to review the publication )

Cell, 2019, 176(1-2):198-212

PubMed: 30503211 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Nat Immunol, 2014, 15(5):439-48

PubMed: 24681565 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

Nat Protoc, 2020, 15(3):1209-1236

PubMed: 32051612 ( click the link to review the publication )

EMBO Rep, 2020, 4;21(3):e49254

PubMed: 32009295 ( click the link to review the publication )

EMBO Rep, 2020, 21:e50162

PubMed: 32314873 ( click the link to review the publication )

J Autoimmun, 2020, 108:102379

PubMed: 31883829 ( click the link to review the publication )

Cells, 2020, 21;9(5):E1280

PubMed: 32455774 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

J Transl Med, 2020, 7;18(1):159

PubMed: 32264925 ( click the link to review the publication )

Cell Signal, 2020, 70:109573

PubMed: 32087304 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(2):343-356

PubMed: 31932908 ( click the link to review the publication )

PLoS One, 2020, 15;15(5):e0232985

PubMed: 32413049 ( click the link to review the publication )

Oncol Lett, 2020, 19(1):460-468

PubMed: 31897159 ( click the link to review the publication )

Pathol Res Pract, 2020, 216(4):152867

PubMed: 32067803 ( click the link to review the publication )

JCI Insight, 2020, 5(4)

PubMed: 32102981 ( click the link to review the publication )

Gastroenterology, 2019, 156(1):187-202

PubMed: 30267710 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4192

PubMed: 31519896 ( click the link to review the publication )
Nat Commun, 2019, 10(1):5324

PubMed: 31757943 ( click the link to review the publication )

Nucleic Acids Res, 2019, 10.1093/nar/gkz1136

PubMed: 31799598 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):33

PubMed: 30728070 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):277

PubMed: 31653272 ( click the link to review the publication )

Elife, 2019, 10.7554/eLife.44306

PubMed: 31050342 ( click the link to review the publication )

Cell Mol Life Sci, 2019, 76(5):1005-1025

PubMed: 30599067 ( click the link to review the publication )

Cancers (Basel), 2019, 11(4)

PubMed: 30935067 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31561534 ( click the link to review the publication )

Br J Cancer, 2019, 121(12):1039-1049

PubMed: 31690832 ( click the link to review the publication )

Cancer Discov, 2019, 9(4):526-545

PubMed: 30709805 ( click the link to review the publication )

Front Immunol, 2019, 10:409

PubMed: 30915074 ( click the link to review the publication )

Mol Oncol, 2019, 10.1002/1878-0261.12607

PubMed: 31782885 ( click the link to review the publication )

J Mol Med (Berl), 2019, 97(7):957-972

PubMed: 31025088 ( click the link to review the publication )

J Immunol, 2019, 203(12):3199-3208

PubMed: 31732526 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786

PubMed: 31694931 ( click the link to review the publication )

Front Oncol, 2019, 9:579

PubMed: 31380285 ( click the link to review the publication )

Arthritis Res Ther, 2019, 21(1):50

PubMed: 30728075 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(12)

PubMed: 31234549 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4437-4449

PubMed: 30670592 ( click the link to review the publication )

Stem Cells Int, 2019, 2019:8451282

PubMed: 30992706 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2019, 22(4):317-328

PubMed: 30668714 ( click the link to review the publication )
Endocrinology, 2019, 160(11):2600-2617

PubMed: 31322702 ( click the link to review the publication )

Skelet Muscle, 2019, 9(1):12

PubMed: 31113472 ( click the link to review the publication )

Biomed Pharmacother, 2019, 115:108570

PubMed: 31054509 ( click the link to review the publication )

Life Sci, 2019, 10.1016/j.lfs.2019.116583

PubMed: 31226417 ( click the link to review the publication )

Cancer Biol Ther, 2019, 20(5):700-710

PubMed: 30571927 ( click the link to review the publication )

Dev Biol, 2019, 449(2):122-131

PubMed: 30826398 ( click the link to review the publication )

Transl Oncol, 2019, 12(4):669-682

PubMed: 30849634 ( click the link to review the publication )

Tuberculosis (Edinb), 2019, 118:101861

PubMed: 31526947 ( click the link to review the publication )

PLoS One, 2019, 14(3):e0213186

PubMed: 30830950 ( click the link to review the publication )

Pain Res Manag, 2019, 2019:1648919

PubMed: 30809320 ( click the link to review the publication )

Oncotarget, 2019, 10(20):1903-1917

PubMed: 30956773 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 10.1016/j.jcmgh.2019.10.005

PubMed: 31654770 ( click the link to review the publication )

eNeuro, 2019, 6(1)

PubMed: 30783618 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):387-401

PubMed: 29200404 ( click the link to review the publication )

Nat Commun, 2018, 9(1):764

PubMed: 29472538 ( click the link to review the publication )

EMBO Rep, 2018, 19(9)

PubMed: 30021835 ( click the link to review the publication )

Int J Cancer, 2018, 143(6):1388-1401

PubMed: 29633255 ( click the link to review the publication )

Neuropsychopharmacology, 2018, 43(8):1779-1788

PubMed: 29760409 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459282 ( click the link to review the publication )

Cell Death Dis, 2018, 9(6):623

PubMed: 29795376 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1081

PubMed: 30349042 ( click the link to review the publication )

Arch Toxicol, 2018, 92(7):2227-2243

PubMed: 29845424 ( click the link to review the publication )

Basic Res Cardiol, 2018, 114(1):3

PubMed: 30446837 ( click the link to review the publication )

Oncoimmunology, 2018, 7(11):e1466018

PubMed: 30377559 ( click the link to review the publication )
Mol Cancer Ther, 2018, 17(9):2013-2023

PubMed: 29934340 ( click the link to review the publication )

Biochim Biophys Acta Mol Basis Dis, 2018, 1864(8):2610-2622

PubMed: 29684588 ( click the link to review the publication )

Oncogenesis, 2018, 7(4):36

PubMed: 29691367 ( click the link to review the publication )

J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(11)

PubMed: 30424007 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(8)

PubMed: 30081552 ( click the link to review the publication )

Sci Rep, 2018, 8(1):8492

PubMed: 29855565 ( click the link to review the publication )

Sci Rep, 2018, 8(1):12886

PubMed: 30150730 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13638

PubMed: 30206377 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9391

PubMed: 29925922 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13072

PubMed: 30166563 ( click the link to review the publication )

Mol Pharmacol, 2018, 94(2):793-801

PubMed: 29880639 ( click the link to review the publication )

Biochem J, 2018, 475(24):3921-3932

PubMed: 30552170 ( click the link to review the publication )

Exp Cell Res, 2018, 371(1):231-237

PubMed: 30107147 ( click the link to review the publication )

Alcohol Clin Exp Res, 2018, 42(11):2160-2171

PubMed: 30103280 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 82(1):65-75

PubMed: 29721849 ( click the link to review the publication )

PLoS One, 2018, 13(11):e0207915

PubMed: 30481203 ( click the link to review the publication )

PLoS One, 2018, 13(3):e0194661

PubMed: 29579087 ( click the link to review the publication )

J Med Virol, 2018, 90(9):1478-1485

PubMed: 29704439 ( click the link to review the publication )

Med Sci Monit, 2018, 24:2620-2630

PubMed: 29704392 ( click the link to review the publication )

Oncol Lett, 2018, 16(2):1967-1974

PubMed: 30008890 ( click the link to review the publication )

JCI Insight, 2018, 3(4)

PubMed: 29467324 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36413-36429

PubMed: 30559927 ( click the link to review the publication )

Curr Protoc Pharmacol, 2018, 81(1):e41

PubMed: 29927058 ( click the link to review the publication )
Oncotarget, 2018, 9(39):25630-25646

PubMed: 29876013 ( click the link to review the publication )

Cond Med, 2018, 1(2):64-72

PubMed: 30135960 ( click the link to review the publication )

Oncotarget, 2018, 9(28):19597-19612

PubMed: 29731968 ( click the link to review the publication )

Oncotarget, 2018, 9(63):32182-32190

PubMed: 30181808 ( click the link to review the publication )

Data Brief, 2018, 17:1314-1319

PubMed: 29876485 ( click the link to review the publication )

Korean J Physiol Pharmacol, 2018, 22(1):23-33

PubMed: 29302209 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13072

PubMed: 30166563 ( click the link to review the publication )

J Clin Invest, 2017, 127(6):2235-2248

PubMed: 28436940 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(11):6334-6349

PubMed: 28369619 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(51):E10981-E10990

PubMed: 29203668 ( click the link to review the publication )

Cell Rep, 2017, 19(4):875-889

PubMed: 28445736 ( click the link to review the publication )

Oncogene, 2017, 36(12):1707-1720

PubMed: 27694895 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(21):3865-3880

PubMed: 28832971 ( click the link to review the publication )

J Med Chem, 2017, 60(13):5334-5348

PubMed: 28581289 ( click the link to review the publication )

Plant Physiol, 2017, 175(4):1760-1773

PubMed: 29018096 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

Cell Chem Biol, 2017, 24(7):858-869

PubMed: 28669525 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Discov, 2017, 7(8):852-867

PubMed: 28408401 ( click the link to review the publication )

Front Immunol, 2017, 8:671

PubMed: 28659914 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(12):2689-2700

PubMed: 28802253 ( click the link to review the publication )

Mol Ther Methods Clin Dev, 2017, 6:54-65

PubMed: 28664166 ( click the link to review the publication )

Eur J Med Chem, 2017, 127:531-553

PubMed: 28109947 ( click the link to review the publication )

J Virol, 2017, 91(16)

PubMed: 28566376 ( click the link to review the publication )
Int J Mol Sci, 2017, 18(5)

PubMed: 28481295 ( click the link to review the publication )

Sci Rep, 2017, 7(1):10921

PubMed: 28883618 ( click the link to review the publication )

Sci Rep, 2017, 7(1):12084

PubMed: 28935977 ( click the link to review the publication )

Sci Rep, 2017, 7(1):8641

PubMed: 28819194 ( click the link to review the publication )

Mech Ageing Dev, 2017, 166:6-15

PubMed: 28843433 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 361(1):140-150

PubMed: 28174211 ( click the link to review the publication )

J Neuropathol Exp Neurol, 2017, 76(12):1000-1007

PubMed: 29136455 ( click the link to review the publication )

J Endocrinol, 2017, 233(3):369-379

PubMed: 28438776 ( click the link to review the publication )

Am J Physiol Renal Physiol, 2017, 312(3):F502-F515

PubMed: 28052874 ( click the link to review the publication )

Int J Cell Biol, 2017, 2017:6169310

PubMed: 28321257 ( click the link to review the publication )

Int J Mol Med, 2017, 40(3):661-672

PubMed: 28677722 ( click the link to review the publication )

Bioorg Med Chem, 2017, 25(7):2105-2132

PubMed: 28259528 ( click the link to review the publication )

PLoS One, 2017, 12(10):e0186620

PubMed: 29045501 ( click the link to review the publication )

Connect Tissue Res, 2017, 58(1):64-75

PubMed: 27404795 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:61-69

PubMed: 28315487 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:11-22

PubMed: 27761810 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:3-10

PubMed: 27761809 ( click the link to review the publication )

Oncotarget, 2017, 8(69):114156-114172

PubMed: 29371976 ( click the link to review the publication )

Oncotarget, 2017, 8(55):93825-93838

PubMed: 29212192 ( click the link to review the publication )

Oncotarget, 2017, 9(3):3172-3187

PubMed: 29423038 ( click the link to review the publication )

Oncotarget, 2017, 8(47):83155-83170

PubMed: 29137331 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4079-4095

PubMed: 27863422 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:375-385

PubMed: 27761836 ( click the link to review the publication )
Oncotarget, 2017, 8(63):107076-107088

PubMed: 29291012 ( click the link to review the publication )

Sci Rep, 2017, 589:97-106

PubMed: 28273598 ( click the link to review the publication )

Nat Microbiol, 2016, 1:16174

PubMed: 27694949 ( click the link to review the publication )

Kidney Int, 2016, 89(2):317-26

PubMed: 26509586 ( click the link to review the publication )

Cancer Res, 2016, 76(10):3067-77

PubMed: 26980768 ( click the link to review the publication )

Cell Death Differ, 2016, 23(8):1312-21

PubMed: 26915294 ( click the link to review the publication )

Sci Signal, 2016, 9(422):ra34

PubMed: 27048565 ( click the link to review the publication )

J Med Chem, 2016, 59(4):1613-33

PubMed: 26681404 ( click the link to review the publication )

Clin Epigenetics, 2016, 8:76

PubMed: 27437033 ( click the link to review the publication )

Clin Epigenetics, 2016, 8:62

PubMed: 27231489 ( click the link to review the publication )

Oncoimmunology, 2016, 5(11):e1219008

PubMed: 27999738 ( click the link to review the publication )

Oncoimmunology, 2016, 5(6):e1164919

PubMed: 27471639 ( click the link to review the publication )

Osteoarthritis Cartilage, 2016, 24(8):1451-60

PubMed: 27072078 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(2):299-312

PubMed: 26772204 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2432-2441

PubMed: 27474150 ( click the link to review the publication )

Pharmacol Res, 2016, 103:328-39

PubMed: 26657418 ( click the link to review the publication )

Transl Psychiatry, 2016, 6(12):e974

PubMed: 27922638 ( click the link to review the publication )

Dis Model Mech, 2016, 9(5):541-52

PubMed: 26989193 ( click the link to review the publication )

J Virol, 2016, 90(20):9018-28

PubMed: 27466424 ( click the link to review the publication )

Front Cell Neurosci, 2016, 10:221

PubMed: 27729849 ( click the link to review the publication )

Front Cell Neurosci, 2016, 9:510

PubMed: 26793062 ( click the link to review the publication )

Sci Rep, 2016, 6:38407

PubMed: 27910927 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2016, 311(1):L124-34

PubMed: 27233998 ( click the link to review the publication )

Am J Pathol, 2016, 186(10):2701-8

PubMed: 27555113 ( click the link to review the publication )
Int J Neuropsychopharmacol, 2016, 10.1093/ijnp/pyw035

PubMed: 27207921 ( click the link to review the publication )

Mol Brain, 2016, 9(1):79

PubMed: 27535553 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(5):546-57

PubMed: 27029345 ( click the link to review the publication )

BMC Cancer, 2016, 10.1186/s12885-016-2353-7

PubMed: 27188282 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2016, 142(11):2263-73

PubMed: 27576506 ( click the link to review the publication )

Biol Chem, 2016, 397(1):75-83

PubMed: 26431101 ( click the link to review the publication )

Methods Enzymol, 2016, 573:161-81

PubMed: 27372753 ( click the link to review the publication )

Sci Rep, 2016, 10.1038/srep28025

PubMed: 27320682 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71696-71702

PubMed: 27765934 ( click the link to review the publication )

Oncotarget, 2016, 7(7):7390-402

PubMed: 26862729 ( click the link to review the publication )

Gene Regul Syst Bio, 2016, 10:9-13

PubMed: 26823649 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6727-47

PubMed: 26734995 ( click the link to review the publication )

Blood, 2015, 5;125(6):941-8

PubMed: 25468569 ( click the link to review the publication )

Nat Commun, 2015, 10.1038/ncomms7537

PubMed: ( click the link to review the publication )

Nat Commun, 2015, 6:7023

PubMed: 25960197 ( click the link to review the publication )

Nat Commun, 2015, 6:6537

PubMed: 26055519 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(14):3230-3240

PubMed: 25813020 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

J Control Release, 2015, 204:20-9

PubMed: 25681050 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 26701908 ( click the link to review the publication )

Cancer Lett, 2015, 366(1):32-43

PubMed: 26028172 ( click the link to review the publication )

Am J Transplant, 2015, 10.1111/ajt.13106

PubMed: 25708614 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: 25490700 ( click the link to review the publication )
J Med Chem, 2015, 58(2):785-800

PubMed: ( click the link to review the publication )

Breast Cancer Res, 2015, 17:26

PubMed: 25848915 ( click the link to review the publication )

Breast Cancer Res, 2015, 17(1):533

PubMed: 25778369 ( click the link to review the publication )

J Neurosci, 2015, 35(3):1250-9

PubMed: 25609639 ( click the link to review the publication )

Br J Cancer, 2015, 112(2):329-37

PubMed: 25514379 ( click the link to review the publication )

Br J Haematol, 2015, 168(3):371-83

PubMed: 25284154 ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(7):3984-94

PubMed: 25896701 ( click the link to review the publication )

Toxicol Sci, 2015, 148(1):220-8

PubMed: 26251326 ( click the link to review the publication )

Sci Rep, 2015, 5:16873

PubMed: 26585834 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2015, 10.1093/ijnp/pyv029

PubMed: 25762717 ( click the link to review the publication )

Front Neurosci, 2015, 9:319

PubMed: 26441495 ( click the link to review the publication )

Breast Cancer Res Treat, 2015, 151(2):281-94

PubMed: 25904215 ( click the link to review the publication )

Virology, 2015, 485:340-54

PubMed: 26331681 ( click the link to review the publication )

J Appl Physiol (1985), 2015, 119(4):342-51

PubMed: 26112243 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144660

PubMed: 26713848 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0137699

PubMed: 26361334 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123901

PubMed: 25875914 ( click the link to review the publication )

Future Virol, 2015, 10(4), 351–356

PubMed: ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(12):1375-85

PubMed: 26297712 ( click the link to review the publication )

Genes Cancer, 2015, 6(5-6):184-213

PubMed: 26124919 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25784-800

PubMed: 26329759 ( click the link to review the publication )

Sheng Li Xue Bao, 2015, 67(5):447-54

PubMed: 26490061 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25801-14

PubMed: 26317649 ( click the link to review the publication )
Sci Transl Med, 2014, 6(256):256ra135

PubMed: 25273096 ( click the link to review the publication )

Genes Dev, 2014, 28(14):1578-91

PubMed: 25030697 ( click the link to review the publication )

PLoS Biol, 2014, 12(1):e1001758

PubMed: 24409098 ( click the link to review the publication )

Int J Cancer, 2014, 10.1002/ijc.28924

PubMed: 24771510 ( click the link to review the publication )

Addict Biol, 2014, 10.1111/adb.12161.

PubMed: 25041570 ( click the link to review the publication )

Br J Haematol, 2014, 167(5):639-50

PubMed: 25155625 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(1):32-7

PubMed: 24165483 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 7):1441-53

PubMed: 24463822 ( click the link to review the publication )

Eur J Immunol, 2014, 44(8):2478-88

PubMed: 24810486 ( click the link to review the publication )

J Biol Chem, 2014, 289(14):9918-25

PubMed: 24515107 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(3):415-27

PubMed: 24248598 ( click the link to review the publication )

Retrovirology, 2014, 11:67

PubMed: 25116364 ( click the link to review the publication )

Neuromolecular Med, 2014, 16(4):727-41

PubMed: 25063076 ( click the link to review the publication )

Pharmacological Reports, 2014, 49–55

PubMed: ( click the link to review the publication )

PLoS One, 2014, 9(11):e113341

PubMed: 25409334 ( click the link to review the publication )

PLoS One, 2014, 9(9):e106784

PubMed: 25198282 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115401

PubMed: 25521755 ( click the link to review the publication )

Pharmacol Rep, 2014, 66(1):49-55

PubMed: 24905306 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 445(2):320-6

PubMed: 24530917 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )

Oncotarget, 2014, 5(12):4516-28

PubMed: 24980831 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Nat Commun, 2013, 4:2735

PubMed: 24193185 ( click the link to review the publication )
Nucleic Acids Res, 2013, 41(12):6018-33

PubMed: 23625969 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2013, 110(28):E2621-8

PubMed: 23788661 ( click the link to review the publication )

Genet Mol Biol, 2013, 36(3):299-307

PubMed: 24130434 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(1):118-27

PubMed: 23091117 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Haematologica, 2013, 98(1):57-64

PubMed: 22801959 ( click the link to review the publication )

Int J Cancer, 2013, 132(9):2076-86

PubMed: 23047626 ( click the link to review the publication )

J Neuroscience, 2013, 33(50):19664-76

PubMed: 24336730 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e655

PubMed: 23744355 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Stem Cells, 2013, 31(7):1434-45

PubMed: 23592435 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(10):2078-87

PubMed: 23939379 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Neurochem, 2013, 129(3):509-15

PubMed: 24147654 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14400-7

PubMed: 23539624 ( click the link to review the publication )

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462 ( click the link to review the publication )

Infect Immun, 2013, 82(2):706-19

PubMed: 24478085 ( click the link to review the publication )

Mol Reprod Dev, 2013, 154(9):1668-79

PubMed: 23693161 ( click the link to review the publication )

Pediatr Nephrol, 2013, 28(10):1909-21

PubMed: 23052657 ( click the link to review the publication )

PLoS One, 2013, 8(9):e74930

PubMed: 24058639 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Exp Hematol, 2013, 41(1):113-23.e2

PubMed: 22989761 ( click the link to review the publication )

Circ Res, 2012, 110(5):739-48

PubMed: 22282194 ( click the link to review the publication )

Mol Cancer Ther, 2012, 11(12):2600-9

PubMed: 23012246 ( click the link to review the publication )
J Neurochem, 2012, 123 Suppl 2:108-15

PubMed: 23050648 ( click the link to review the publication )

J Immunol, 2012, 189(4):1792-9

PubMed: 22786766 ( click the link to review the publication )

Eur Neuropsychopharmacol, 2012, 22(9):651-6

PubMed: 22341945 ( click the link to review the publication )

J Am Heart Assoc, 2012, 1(3):e000901

PubMed: 23130137 ( click the link to review the publication )

J Virol, 2012, 86(6):3073-87

PubMed: 22238308 ( click the link to review the publication )

PLoS One, 2012, 7(7):e41776

PubMed: 22848598 ( click the link to review the publication )

Biochem Biophys Res Commun, 2012, 428(1):121-6

PubMed: 23063976 ( click the link to review the publication )

Biomol Ther (Seoul), 2012, 20(1):81-8

PubMed: 24116279 ( click the link to review the publication )

Brain, 2011, 134(Pt 8):2408-21

PubMed: 21772061 ( click the link to review the publication )

J Thorac Oncol, 2011, 6(7):1152-61

PubMed: 21597390 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2011, 108(49):19629-34

PubMed: 22106282 ( click the link to review the publication )

J Neurosci, 2011, 31(11):3990-9

PubMed: 21411642 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 414(1):25-30

PubMed: 21925145 ( click the link to review the publication )

J Biomed Biotechnol, 2011, 2011:371832

PubMed: 21151613 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

Mol Pain, 2010, 6:51

PubMed: 20822541 ( click the link to review the publication )

PLoS One, 2010, 5(12):e14335

PubMed: 21179472 ( click the link to review the publication )

PLoS One, 2010, 5(12):e14462

PubMed: 21283510 ( click the link to review the publication )

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述

靶点

HDAC1 ^[2] (Cell-free assay)	HDAC3 ^[2] (Cell-free assay)
0.51 μM	1.7 μM

体外研究

MS-275通过作用于2′-氨基而抑制HDACs。MS-275作用于 K562细胞，诱导 p21^WAF1/CIP1和凝溶胶蛋白的累积。MS-275作用于A2780细胞，可以降低S期细胞，提高G1期细胞。 MS-275通过抑制HAD而抑制人类肿瘤细胞系，包括 A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St和 HCT-15细胞增殖， IC50 为41.5 nM到4.71 μM。^[1]MS-275抑制HDACs，作用于HDAC1和 HDAC3时IC50 分别为0.51 μM和1.7 μM。而对其他的HDACs没有抑制效果，如HDAC4, 6, 8和10。^[2]MS-275有效抑制人类白血病和淋巴癌细胞，包括U937, HL-60, K562, 和Jurkat。MS-275可以诱导U937细胞p21CIP1/WAF1 调节的生长和变异Marker (CD11b)的表达。MS-275降低cyclin D1和抗凋亡蛋白Mcl-1与XIAP的表达。^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
SCC-3	MkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M336cWlEPTB;MD6wOlEh\|ryP	MmjvV2FPT0WU
ALL-PO	M4jEfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTBwME[zOVUh\|ryP	MXXTRW5ITVJ?
697	NH\XRpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTBwMEm5O\|Yh\|ryP	MnvQV2FPT0WU
NCI-H748	NYTiWnk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTBwMUCzN\|Qh\|ryP	NGHJOmpUSU6JRWK=
NKM-1	M4i0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\mV2k4UUN3ME2wMlExQTF{IN88US=>	NFPuS29USU6JRWK=
ES1	NEjhRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHkTWM2OD1yLkGxNlU2KM7:TR?=	M4\FSXNCVkeHUh?=
NCI-H1963	M4Xwc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2[1cmlEPTB;MD6xNVU4QSEQvF2=	NXT1RmtbW0GQR1XS
NCI-H1417	NWXGO3hsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\H[3NKSzVyPUCuNVI6PzRizszN	NYrEbFg1W0GQR1XS
NEC8	NFjNfVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXkb5RoUUN3ME2wMlE{PTJ5IN88US=>	NYPUdmhuW0GQR1XS
CRO-AP2	NEDXNlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTBwMU[4PFkh\|ryP	NXP0TIFRW0GQR1XS
A3-KAW	M2jZfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH:wOIZKSzVyPUCuNVc3OjdizszN	NUHlN\|VFW0GQR1XS
SF539	NXzB[G1IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEf0R3NKSzVyPUCuNVk2QTNizszN	M4XKRXNCVkeHUh?=
NOS-1	NVTR[JU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUG4b4c2UUN3ME2wMlE6PjF7IN88US=>	NF3oUZNUSU6JRWK=
NTERA-S-cl-D1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmH6TWM2OD1yLkKwNVE{KM7:TR?=	MkDlV2FPT0WU
COR-L88	NI[5R4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\ZN2lEPTB;MD6yNlk2QSEQvF2=	NFXRU3hUSU6JRWK=
EM-2	NFjSN2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYXqbVhqUUN3ME2wMlI1ODd7IN88US=>	NXLuSFg6W0GQR1XS
KARPAS-45	NFnENW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3QTWM2OD1yLkK3PFM{KM7:TR?=	Mmn2V2FPT0WU
DSH1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfvSZJmUUN3ME2wMlI5PzB6IN88US=>	NUCzXHZEW0GQR1XS
HT-144	NYWxNGZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLqTWM2OD1yLkOwNlU3KM7:TR?=	NVPoTW95W0GQR1XS
ATN-1	NXvVXWhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnSOoVVUUN3ME2wMlMxPTd4IN88US=>	NEXuXpJUSU6JRWK=
HEL	MoLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTBwM{GzOFgh\|ryP	NGjGPWZUSU6JRWK=
NB12	Mnj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1ntNWlEPTB;MD6zNVc2PiEQvF2=	MV;TRW5ITVJ?
LU-139	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHiwNFNKSzVyPUCuN\|M2OSEQvF2=	MkLxV2FPT0WU
J-RT3-T3-5	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEKxeIZKSzVyPUCuN\|M4OTZizszN	MWnTRW5ITVJ?
MOLT-13	NF;ofnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjYbW9KSzVyPUCuN\|M5OSEQvF2=	M4XZWnNCVkeHUh?=
SR	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHu4UoFKSzVyPUCuN\|QzPjFizszN	NUXJdJhSW0GQR1XS
CMK	NXHoSGFtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTBwM{W3Nlch\|ryP	NX3uXIZvW0GQR1XS
ES8	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXHWHdKSzVyPUCuN\|YxOjJizszN	MljyV2FPT0WU
LB647-SCLC	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIqwe2dKSzVyPUCuN\|Y4OyEQvF2=	MlzrV2FPT0WU
TE-8	MmnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3W1UWlEPTB;MD6zOlk{PSEQvF2=	MkHzV2FPT0WU
BV-173	MnHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfYOHFKSzVyPUCuN\|cyOjFizszN	MYPTRW5ITVJ?
DEL	NG\tcGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\ueG1KSzVyPUCuN\|c1QDdizszN	MULTRW5ITVJ?
ARH-77	MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHD[HFKSzVyPUCuN\|gyQTNizszN	MYTTRW5ITVJ?
NCCIT	NILMb3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\PTWVYUUN3ME2wMlM5PjR7IN88US=>	MUXTRW5ITVJ?
RPMI-8402	M3T2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPMTWM2OD1yLkO4O\|AyKM7:TR?=	M3rlenNCVkeHUh?=
MONO-MAC-6	MnO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnIdWlKSzVyPUCuN\|g4PzZizszN	NEDsfW9USU6JRWK=
SK-MM-2	NVTUcFRST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DWTmlEPTB;MD6zPVg3QCEQvF2=	NFHjS5ZUSU6JRWK=
CHP-126	NIPyd25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHOTWM2OD1yLkSwNlMyKM7:TR?=	MnPHV2FPT0WU
A101D	MnLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrmNJBKSzVyPUCuOFA{KM7:TR?=	NGDISXpUSU6JRWK=
SCH	MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XPcWlEPTB;MD60NFM1OiEQvF2=	NFTiTJlUSU6JRWK=
NMC-G1	NYC0cYVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXaTWM2OD1yLkSwN\|Y4KM7:TR?=	M4jSe3NCVkeHUh?=
NCI-H209	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4SzcGlEPTB;MD60NFYyOyEQvF2=	MXzTRW5ITVJ?
MOLT-16	M{\XfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PUSmlEPTB;MD60NVAyPyEQvF2=	NGjqOZNUSU6JRWK=
RPMI-6666	NIiwc4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHnTWM2OD1yLkSxNVIh\|ryP	NHrvdVFUSU6JRWK=
OPM-2	M3LDcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDyTWM2OD1yLkSxOVE{KM7:TR?=	MXnTRW5ITVJ?
MRK-nu-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWH1U2s4UUN3ME2wMlQ{OTV\|IN88US=>	MnXKV2FPT0WU
BC-1	M3[wXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mne0TWM2OD1yLkSzOFA{KM7:TR?=	NX[1[YVWW0GQR1XS
MHH-NB-11	M121N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTBwNEO0OVMh\|ryP	MVTTRW5ITVJ?
Ramos-2G6-4C10	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTBwNEO4PVch\|ryP	NUDQ[JFCW0GQR1XS
LS-513	MmXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvkUWd{UUN3ME2wMlQ1PTBzIN88US=>	M4q1XXNCVkeHUh?=
K5	M3K5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTBwNEewNlUh\|ryP	MkHIV2FPT0WU
HOP-62	NH;WSohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTBwNEizOVgh\|ryP	MWHTRW5ITVJ?
NCI-H187	NIjVPY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTBwNEmyNlch\|ryP	MYXTRW5ITVJ?
BE-13	Mk\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnpRnd2UUN3ME2wMlQ6PjZzIN88US=>	M3T3OXNCVkeHUh?=
HC-1	NFPOUZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXpTWM2OD1yLkWwOFc{KM7:TR?=	MX\TRW5ITVJ?
ACN	NV:4V3hJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTBwNUGwNlgh\|ryP	MnvrV2FPT0WU
HCC1599	M37rV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUH4VlNtUUN3ME2wMlUyPTdizszN	MXzTRW5ITVJ?
MV-4-11	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTBwNUOwOFEh\|ryP	M3GxdXNCVkeHUh?=
LC-2-ad	M4HCfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTBwNUO2OlMh\|ryP	MYLTRW5ITVJ?
HL-60	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLhTWM2OD1yLkW0NlYyKM7:TR?=	M1\ybHNCVkeHUh?=
NB17	MmfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTBwNUSzPEDPxE1?	NIDVUYhUSU6JRWK=
TE-1	NGC4OJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnNTFVKSzVyPUCuOVU{ODZizszN	MnTBV2FPT0WU
NCI-H524	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTBwNUW0NFEh\|ryP	MUTTRW5ITVJ?
MZ7-mel	NHPtcZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrtS4RKSzVyPUCuOVYyODVizszN	NIDWflhUSU6JRWK=
L-363	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrhS4hKSzVyPUCuOVY3PTdizszN	NFn4dnNUSU6JRWK=
BL-41	M4LxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37FZ2lEPTB;MD61Olg5QSEQvF2=	NUnUVmFmW0GQR1XS
LU-134-A	M2TEW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFPIRZJKSzVyPUCuOVcxPzNizszN	NXzRfFhTW0GQR1XS
SIG-M5	MkD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3L0SmlEPTB;MD61O\|g1QCEQvF2=	NFnyN4dUSU6JRWK=
ONS-76	NX7ldGJGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlv0TWM2OD1yLkW4NlQzKM7:TR?=	MmjTV2FPT0WU
KARPAS-299	NITDN2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;O[oF1UUN3ME2wMlU5PTB2IN88US=>	NXrBdVlHW0GQR1XS
DU-4475	MoOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1WxNmlEPTB;MD61PFcxOyEQvF2=	MXTTRW5ITVJ?
NB69	NHntXZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTBwNUm4NlUh\|ryP	M2XobHNCVkeHUh?=
MHH-PREB-1	NU[0bphWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTZUVJwUUN3ME2wMlYxPzF7IN88US=>	MkTEV2FPT0WU
LU-165	NEHyeHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHtTWM2OD1yLk[xPFEzKM7:TR?=	NWDyPZFQW0GQR1XS
LOUCY	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2L6[GlEPTB;MD62N\|M3PCEQvF2=	MmHQV2FPT0WU
NCI-H526	M4LjcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUC5fJI5UUN3ME2wMlY{PTRzIN88US=>	MYLTRW5ITVJ?
KE-37	M{HZNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3HhWGlEPTB;MD62OFI4PiEQvF2=	NIHJWJdUSU6JRWK=
NALM-6	NXL3UmV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTBwNkS4OkDPxE1?	Mo[1V2FPT0WU
CW-2	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXGcW9KSzVyPUCuOlU4QTRizszN	M3\nTHNCVkeHUh?=
SU-DHL-1	NIW1NVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\oZmlEPTB;MD62OVk1PyEQvF2=	NXX2UGZTW0GQR1XS
NB13	Mle2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHlboJKSzVyPUCuOlY5OTdizszN	M4fONHNCVkeHUh?=
QIMR-WIL	NEPjN\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLuTWM2OD1yLk[4N\|Q{KM7:TR?=	MkD4V2FPT0WU
ECC12	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVW0UpIxUUN3ME2wMlcxODh4IN88US=>	MXHTRW5ITVJ?
KALS-1	NF;6WppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPSb\|VKSzVyPUCuO\|A1QTJizszN	MmfWV2FPT0WU
COR-L279	NHXKXopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWG2e2FnUUN3ME2wMlcxQTl4IN88US=>	NWPBZnh7W0GQR1XS
NB14	M{DsfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYn1O2szUUN3ME2wMlczPjF5IN88US=>	NV;MXoJjW0GQR1XS
CCRF-CEM	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LNNmlEPTB;MD63OFY3OSEQvF2=	NFH5[oJUSU6JRWK=
SW954	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUe0OmRwUUN3ME2wMlc2QTl7IN88US=>	NGfjWZRUSU6JRWK=
IST-SL1	NHvPdpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\3XXlNUUN3ME2wMlc4OzR6IN88US=>	NXPrb2VqW0GQR1XS
LAMA-84	NIn0NZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTBwN{e1Olch\|ryP	NHrQcVBUSU6JRWK=
Daudi	NXXUPY14T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rhUWlEPTB;MD63O\|Y5OSEQvF2=	NFznfHZUSU6JRWK=
BC-3	NIHXcHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTBwN{izNFgh\|ryP	MWjTRW5ITVJ?
HCC2998	NUn3[VRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3nS3lqUUN3ME2wMlc5OzZizszN	NVO4XYtnW0GQR1XS
NCI-H69	NIni[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml31TWM2OD1yLkiwNVQ4KM7:TR?=	MkjMV2FPT0WU
CPC-N	Ml3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfnOXlKSzVyPUCuPFA2OjRizszN	M1TCNXNCVkeHUh?=
NOMO-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml2yTWM2OD1yLkixNFg1KM7:TR?=	MYTTRW5ITVJ?
CESS	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTBwOEGxPVch\|ryP	M1:xfHNCVkeHUh?=
LC4-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3n3ZmlEPTB;MD64OFAxPyEQvF2=	NF35O5pUSU6JRWK=
BL-70	MkPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHnTWM2OD1yLki1O\|AzKM7:TR?=	MX7TRW5ITVJ?
ES4	M4rGPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfxbJZKSzVyPUCuPFU5PjhizszN	MlzRV2FPT0WU
HCE-T	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonzTWM2OD1yLki3NVcyKM7:TR?=	M{HuWHNCVkeHUh?=
JAR	MnXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTBwOEe4Nlch\|ryP	M{XLb3NCVkeHUh?=
ST486	NXPMeHJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mkf1TWM2OD1yLki3PVE4KM7:TR?=	NELJfYhUSU6JRWK=
KS-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGK3UZNKSzVyPUCuPFgxQTZizszN	M2\NZnNCVkeHUh?=
GDM-1	MlLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTBwOEi2PFch\|ryP	NXK0U\|lZW0GQR1XS
EHEB	MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTBwOUK1PFUh\|ryP	NXywO5puW0GQR1XS
LB2518-MEL	NGe4PYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHvXHpzUUN3ME2wMlk{Ojh2IN88US=>	NFfKVFFUSU6JRWK=
GOTO	NGnmWpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mly4TWM2OD1yLkm1NFc3KM7:TR?=	NEfMV5NUSU6JRWK=
LXF-289	MmjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrT[XNKSzVyPUCuPVU6ODFizszN	NIrNPZRUSU6JRWK=
ES6	NIHvdolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLPV\|ZLUUN3ME2wMlk3PDN5IN88US=>	NH\1ZXlUSU6JRWK=
OS-RC-2	NF\Bb\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTBwOU[4N{DPxE1?	MmSyV2FPT0WU
DMS-153	M1TRdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGP0SXdKSzVyPUCuPVc1PjlizszN	NFzNNWhUSU6JRWK=
SK-PN-DW	NXrY[YczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn23TWM2OD1yLkm3PFMyKM7:TR?=	NFTsUJZUSU6JRWK=
HH	Mk\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUO3Npk5UUN3ME2wMlk5QTV7IN88US=>	NGHYNWpUSU6JRWK=
SH-4	MknaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NELzOIJKSzVyPUGuNFI1OSEQvF2=	NUe5fIM1W0GQR1XS
MOLT-4	NHLlb3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LqPGlEPTB;MT6wN\|Q2PCEQvF2=	M2\aTnNCVkeHUh?=
TGW	NHzQdZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTFwMEe2O\|Uh\|ryP	M4KxU3NCVkeHUh?=
L-540	MmXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\0TWM2OD1zLkGwOlA1KM7:TR?=	NGXvZplUSU6JRWK=
PF-382	NVL5bIdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUX5VGxYUUN3ME2xMlEyPTF\|IN88US=>	NUTudlB3W0GQR1XS
LC-1F	M4n0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTFwMUKwNFch\|ryP	MkS5V2FPT0WU
OVCAR-4	NX64dm1tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mom4TWM2OD1zLkGzNVY2KM7:TR?=	NWTKPIFzW0GQR1XS
A4-Fuk	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTFwMUWzOlQh\|ryP	NVjobIxGW0GQR1XS
HCC2218	NEe4Vm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTFwMU[2OFEh\|ryP	M3rNfXNCVkeHUh?=
HAL-01	NHnrSG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTFwMU[5OFMh\|ryP	MWjTRW5ITVJ?
IST-MEL1	NUjsUZM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTFwMUe2OVkh\|ryP	NGHtVndUSU6JRWK=
NCI-H719	NX33XHNKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrEUphKSzVyPUGuNVc5QThizszN	MYDTRW5ITVJ?
EVSA-T	NULicmMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\ubmlEPTB;MT6xPFEyPCEQvF2=	NIPCOoxUSU6JRWK=
SK-NEP-1	NVm3VJBlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTFwMkCyOlYh\|ryP	Mkm1V2FPT0WU
OCUB-M	NV\lWXNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXZNG5KSzVyPUGuNlE1QDlizszN	M1\INnNCVkeHUh?=
MEG-01	NUPqNXBFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzndYdFUUN3ME2xMlIzOTF6IN88US=>	M{HVdXNCVkeHUh?=
no-10	M4DNemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml3UTWM2OD1zLkKzNVEzKM7:TR?=	NW\OT2RzW0GQR1XS
MHH-CALL-2	NVKxNm1qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkSyTWM2OD1zLkK0O\|IyKM7:TR?=	MXvTRW5ITVJ?
SK-N-DZ	MmPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;4R4tzUUN3ME2xMlI1Pzd4IN88US=>	M2LIZnNCVkeHUh?=
SCLC-21H	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDXTWM2OD1zLkK2OFc5KM7:TR?=	MmDnV2FPT0WU
CTV-1	NW\wWFB2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXqSGlLUUN3ME2xMlI4PDJ3IN88US=>	NUSwW\|YyW0GQR1XS
NB1	M1G2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NID1T4ZKSzVyPUGuNlc4OzJizszN	MlfQV2FPT0WU
NCI-H64	M2\leWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEn5bHhKSzVyPUGuNlg1PjJizszN	MWPTRW5ITVJ?
MDA-MB-134-VI	NXTsOFlqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPYcY9KSzVyPUGuNlg2PzdizszN	NYX2RoFuW0GQR1XS
LB2241-RCC	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTHVY5mUUN3ME2xMlI5PjZ\|IN88US=>	NIO3[4dUSU6JRWK=
8-MG-BA	Ml3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFP6cYxKSzVyPUGuNlg5PjZizszN	MnzVV2FPT0WU
LP-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTueYZ3UUN3ME2xMlI6QTR5IN88US=>	Mn:2V2FPT0WU
LS-411N	M3XpUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2XCW2lEPTB;MT6zNFk6QCEQvF2=	NH\qTnNUSU6JRWK=
CAL-148	MoPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M33uU2lEPTB;MT6zNlU1OiEQvF2=	M36xZ3NCVkeHUh?=
NCI-H2171	NHH5eIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PSUGlEPTB;MT6zOFUxOiEQvF2=	M4jvW3NCVkeHUh?=
JiyoyeP-2003	MmDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTFwM{WzPUDPxE1?	M1TDNHNCVkeHUh?=
NCI-H2107	Mn\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnaPJQ2UUN3ME2xMlM2QDh\|IN88US=>	M2X6TnNCVkeHUh?=
BB30-HNC	NVK5fYlzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYLFd3I6UUN3ME2xMlM5QTd6IN88US=>	NVnDOo1mW0GQR1XS
K-562	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;rOmdKSzVyPUGuN\|kzOTlizszN	MnX1V2FPT0WU
PSN1	NHTXPJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTwbXBKSzVyPUGuOFIzQDdizszN	NG\DbpdUSU6JRWK=
HCC2157	NXf5NGNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzoN5NKSzVyPUGuOFI3QTFizszN	M4nubHNCVkeHUh?=
SBC-1	NGLYUWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\tTIpKSzVyPUGuOFI4PDFizszN	M{Tie3NCVkeHUh?=
MC116	NF[yN5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXXJR\|UxRTFwNEO2NVUh\|ryP	NYHiWFY4W0GQR1XS
KARPAS-422	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVzMV\|NJUUN3ME2xMlQ2OzV6IN88US=>	NXnXSolCW0GQR1XS
LB996-RCC	NV3zPZJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4D6WmlEPTB;MT60O\|ExOyEQvF2=	NUTSVWtwW0GQR1XS
MSTO-211H	NU\2ZVVlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzrVWJKSzVyPUGuOFc6QDdizszN	M4qwfXNCVkeHUh?=
BT-474	M32yZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3VXINKSzVyPUGuOVE4PjRizszN	NUTBOllxW0GQR1XS
A388	NV24[HhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTFwNUG5OFUh\|ryP	NFvlNXpUSU6JRWK=
SJSA-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3O1NWlEPTB;MT61NlI3KM7:TR?=	MkDiV2FPT0WU
COLO-829	M4Xt[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LvRWlEPTB;MT61N\|U3PCEQvF2=	M1rvbHNCVkeHUh?=
KM-H2	M3vVdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTFwNU[2O{DPxE1?	MVzTRW5ITVJ?
GR-ST	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\6eGlEPTB;MT61OlgzKM7:TR?=	NI\wS3dUSU6JRWK=
RPMI-8866	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTqd2lsUUN3ME2xMlYxOTR2IN88US=>	MXPTRW5ITVJ?
KG-1	NXfHelE2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;vbINKSzVyPUGuOlE6ODFizszN	M{XzS3NCVkeHUh?=
NCI-H82	NV7QPGVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLObWpKSzVyPUGuOlM1ODZizszN	NU[3XGZNW0GQR1XS
LB1047-RCC	NXLvR\|lMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInmeFNKSzVyPUGuOlM1PTlizszN	M{f4TXNCVkeHUh?=
KM12	Mn;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHKdFBKSzVyPUGuOlQ4KM7:TR?=	NUT4fJpZW0GQR1XS
NB5	NG[3eVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HmWGlEPTB;MT62OVY4PyEQvF2=	NGq0fFRUSU6JRWK=
HDLM-2	NVHybYNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXvZmNKSzVyPUGuOlgzQDFizszN	M4G4dnNCVkeHUh?=
KU812	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTFwNkm2NFUh\|ryP	MXvTRW5ITVJ?
DB	M3LOcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGKydYFKSzVyPUGuO\|A{PTNizszN	NGX2VoRUSU6JRWK=
HD-MY-Z	MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTFwN{WyN\|Qh\|ryP	MXrTRW5ITVJ?
KURAMOCHI	NXTaNXZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHpTWM2OD1zLke3NlA4KM7:TR?=	MWTTRW5ITVJ?
ETK-1	M{nKWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnm5TWM2OD1zLke4PFc6KM7:TR?=	MoriV2FPT0WU
SK-UT-1	MoH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUnES2VqUUN3ME2xMlc6Ozh6IN88US=>	Mkm1V2FPT0WU
HUTU-80	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnjoTWM2OD1zLke5OVA5KM7:TR?=	NYnh[VdPW0GQR1XS
ES7	NIK2Z2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIfLfIhKSzVyPUGuPFA{ODJizszN	MX;TRW5ITVJ?
SW872	NXvSNmlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTFwOEGzPVUh\|ryP	MXTTRW5ITVJ?
TK10	NGf3NHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnZTWM2OD1zLkizNVA5KM7:TR?=	NFHweXVUSU6JRWK=
LB831-BLC	NFnSRXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HFVmlEPTB;MT64N\|U3OyEQvF2=	M{nNTnNCVkeHUh?=
TE-9	M4HpPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLvNZpMUUN3ME2xMlg1PDJ{IN88US=>	NID4SI9USU6JRWK=
MLMA	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\TfXdKSzVyPUGuPFgzOzRizszN	NIr1cmdUSU6JRWK=
D-542MG	NYPBdHBvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXu0cGtwUUN3ME2xMlg6Ozd\|IN88US=>	MULTRW5ITVJ?
EW-16	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTFwOUK3NkDPxE1?	NXmwTpdXW0GQR1XS
LOXIMVI	MnXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTFwOUOyPEDPxE1?	MWHTRW5ITVJ?
GB-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTXTWM2OD1zLkmzPFY3KM7:TR?=	NEXHZ3VUSU6JRWK=
IST-SL2	NUnGXll4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFOzfG5KSzVyPUKuNFAzPjJizszN	NUfxU25VW0GQR1XS
LAN-6	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXlenU3UUN3ME2yMlAyQTZ4IN88US=>	Ml7EV2FPT0WU
NCI-H510A	NVWxXJFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTJwMES1NFIh\|ryP	NXr4RlhMW0GQR1XS
NCI-H1092	M1jsbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTJwMEWxNlQh\|ryP	Mn3xV2FPT0WU
HT	M{PKfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrtZZNKSzVyPUKuNVA1PTRizszN	NULpPY1HW0GQR1XS
RL95-2	NHPDXIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTJwMUG0PFIh\|ryP	NGP2ZWVUSU6JRWK=
NCI-H1355	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHraXYdKSzVyPUKuNVE4QTJizszN	MnfWV2FPT0WU
NCI-H720	NVjpc\|hkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTJwMU[4O\|Mh\|ryP	MmDIV2FPT0WU
NCI-H1522	MlLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonETWM2OD1{LkKxO\|I{KM7:TR?=	MWjTRW5ITVJ?
LB373-MEL-D	NHKyTllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mne5TWM2OD1{LkK2PVAzKM7:TR?=	M{n6[3NCVkeHUh?=
DG-75	MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTJwMkexOFgh\|ryP	NEXUTodUSU6JRWK=
ML-2	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3GTWM2OD1{LkOyPFU2KM7:TR?=	MYLTRW5ITVJ?
SF126	NXXiNGZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\XWJNKSzVyPUKuN\|MxQTRizszN	M13ZbnNCVkeHUh?=
MPP-89	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnS3TWM2OD1{LkOzNVQ2KM7:TR?=	NFq4WItUSU6JRWK=
NCI-H345	NGfpclBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmr2TWM2OD1{LkOzNlc4KM7:TR?=	NI\mcWZUSU6JRWK=
LS-123	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTPZ5JzUUN3ME2yMlM1QTN4IN88US=>	M3\NVXNCVkeHUh?=
NB10	MoDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7RTWM2OD1{LkSxNFkzKM7:TR?=	MoPRV2FPT0WU
CGTH-W-1	M{fPUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYiwXWhPUUN3ME2yMlQzOjZ5IN88US=>	NGDXSWhUSU6JRWK=
CP66-MEL	NX;vcJA1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTqbVBpUUN3ME2yMlQ4PzdizszN	MXvTRW5ITVJ?
L-428	MojwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXMUlVlUUN3ME2yMlQ5PTJzIN88US=>	Ml3UV2FPT0WU
DMS-79	NWW2[HJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPubo9KSzVyPUKuOVQyODNizszN	M4HEV3NCVkeHUh?=
NCI-H1882	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2O2bWlEPTB;Mj62O\|U3OiEQvF2=	M33jWHNCVkeHUh?=
KGN	M3jRVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\uTWM2OD1{Lke2PFc3KM7:TR?=	NYHSRnRRW0GQR1XS
EW-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPXcm5pUUN3ME2yMlc4ODh\|IN88US=>	MVLTRW5ITVJ?
U-266	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;PemlEPTB;Mj64OFgzOyEQvF2=	NHPGR\|hUSU6JRWK=
COLO-320-HSR	NHLLXm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PHbmlEPTB;Mj64OVY1OSEQvF2=	NULlOlNUW0GQR1XS
KMOE-2	MoXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTJwOEe3NVEh\|ryP	Ml7YV2FPT0WU
BB49-HNC	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXrTWM2OD1{LkmyOFgh\|ryP	NYPhWZhIW0GQR1XS
GI-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXoTWM2OD1{LkmyPVU4KM7:TR?=	M4jI[3NCVkeHUh?=
NCI-H1304	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTNwMEC1NVEh\|ryP	M{\pXXNCVkeHUh?=
NCI-H2227	NWPnbWlXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLLS3BKSzVyPUOuNFIxPzlizszN	MWjTRW5ITVJ?
U-87-MG	Ml3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTNwMEO1NVMh\|ryP	MnW2V2FPT0WU
NCI-H747	NU\GO5dpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXyTplKSzVyPUOuNFUzODZizszN	NIPqfHhUSU6JRWK=
CTB-1	M3H5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2jtUWlEPTB;Mz6wOVM4PiEQvF2=	NVrRU\|c{W0GQR1XS
RPMI-8226	NWTPbWFUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4na[mlEPTB;Mz6xOFM4QCEQvF2=	MmPFV2FPT0WU
NCI-H2141	NHzVbZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\DRWlEPTB;Mz6xOlU3PiEQvF2=	NH7G[5dUSU6JRWK=
IST-MES1	NVTjToN7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGiyeGFKSzVyPUOuNVgzPzlizszN	NXHSRlQ4W0GQR1XS
TE-5	NUm3cmNqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXOe3JKSzVyPUOuNlE{PDJizszN	MnrnV2FPT0WU
UACC-257	M2Dne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTNwNEO2OVkh\|ryP	MmHyV2FPT0WU
SK-N-FI	MlKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPLW5NQUUN3ME2zMlQ2OjJ5IN88US=>	NW\pZ\|FMW0GQR1XS
MFH-ino	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1u3fGlEPTB;Mz60OlU5QSEQvF2=	MnPnV2FPT0WU
SF268	NH3yfGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzKZlk3UUN3ME2zMlQ5OTd2IN88US=>	NEDwSIhUSU6JRWK=
TE-12	NEnMfJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4nzVWlEPTB;Mz61NVY6QSEQvF2=	MY\TRW5ITVJ?
NB6	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTNwNUW1OlMh\|ryP	NYXZPYRmW0GQR1XS
DJM-1	M17wUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3q5RWlEPTB;Mz61PVg6QSEQvF2=	M1nVNnNCVkeHUh?=
MZ1-PC	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzPTWM2OD1\|Lk[xOlI1KM7:TR?=	NVrNNoE3W0GQR1XS
OCI-AML2	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mly1TWM2OD1\|Lk[yOlcyKM7:TR?=	NGXOOlhUSU6JRWK=
NCI-H1155	NI\4S3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTCd2l3UUN3ME2zMlcxQTR5IN88US=>	MXXTRW5ITVJ?
RKO	Mkm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPMNo1wUUN3ME2zMlc4OTh7IN88US=>	MYDTRW5ITVJ?
ECC4	NUToW4RWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rtZWlEPTB;Mz65O\|E6PSEQvF2=	Mn3EV2FPT0WU
BB65-RCC	NWHFWGVzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTNwOUe1OFch\|ryP	MWHTRW5ITVJ?
EB-3	MnXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPlZ3NKSzVyPUOuPVk3OzNizszN	NWDGXmhNW0GQR1XS
SHP-77	M{nLb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mkm0TWM2OD12LkCwOVI1KM7:TR?=	NYTHS41HW0GQR1XS
NCI-H2196	NWm0WWpoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPPTWM2OD12LkC1OlI2KM7:TR?=	M3nYT3NCVkeHUh?=
GI-ME-N	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjzV4lKSzVyPUSuNFY{QTlizszN	NVXDV4l2W0GQR1XS
MN-60	M3\pdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVG4fnZ4UUN3ME20MlExQDdizszN	M1LQV3NCVkeHUh?=
NCI-H1694	NGX4NIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NES2O4ZKSzVyPUSuNVM1ODVizszN	Mm[5V2FPT0WU
LU-65	NWfUcFQxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHSTWM2OD12LkG1N\|MzKM7:TR?=	NXzsSWRYW0GQR1XS
NCI-H1436	NFrsSIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTRwMUizN\|Mh\|ryP	MlPLV2FPT0WU
KINGS-1	M1zIRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nTdGlEPTB;ND6zNVQ{OiEQvF2=	MkXBV2FPT0WU
GT3TKB	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzIfmJKSzVyPUSuN\|MzPjhizszN	M{S0ZXNCVkeHUh?=
Becker	NX21OXlUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jHTWlEPTB;ND6zO\|MyOiEQvF2=	MVvTRW5ITVJ?
HCC1187	MkjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnToTWM2OD12Lki5OlU4KM7:TR?=	NEDKNXVUSU6JRWK=
D-502MG	NX\EfHE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\3XJZlUUN3ME21MlAxPDF4IN88US=>	NUnTdmZwW0GQR1XS
VA-ES-BJ	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4njOWlEPTB;NT6xN\|c4QCEQvF2=	MUPTRW5ITVJ?
NB7	NIDBVY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTVwMUSxNVIh\|ryP	NG\ubI9USU6JRWK=
SW962	NGDtZndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPFTWM2OD13LkO4PFE1KM7:TR?=	Ml\LV2FPT0WU
no-11	M370U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfFOGFKSzVyPUWuO\|Y{PDNizszN	Mm\hV2FPT0WU
KNS-81-FD	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rGWGlEPTB;NT65NFY6PCEQvF2=	NVfOTlR3W0GQR1XS
COLO-684	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfjTWM2OD13Lkm5OFk1KM7:TR?=	NFvSTndUSU6JRWK=
D-263MG	NFrrTJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrJ[VZkUUN3ME22MlA5QDl3IN88US=>	NHjTNmxUSU6JRWK=
EW-24	M33yXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTZwMki1NUDPxE1?	NWHPdGsyW0GQR1XS
TE-10	NGG4U\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofTTWM2OD14LkSyOlI{KM7:TR?=	MXLTRW5ITVJ?
EKVX	MmfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnDTGJKSzVyPU[uOFY{OjFizszN	NF7oNmtUSU6JRWK=
NCI-H1648	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvETWM2OD14Lk[3OVU4KM7:TR?=	NEjSfXhUSU6JRWK=
LB771-HNC	M1HIfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTZwOUKzNFEh\|ryP	MWrTRW5ITVJ?
SK-MEL-1	M3nDcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXnJR\|UxRThwMUOxOlYh\|ryP	M1vWRXNCVkeHUh?=
COLO-668	NGjzW\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHPU5pKSzVyPUiuNlc4QDZizszN	M1HOTXNCVkeHUh?=
EW-12	M{TrW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRThwNEC4NFMh\|ryP	NELrW5dUSU6JRWK=
A253	NIPzboFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRThwOES2OlEh\|ryP	M1H6VnNCVkeHUh?=
NCI-H2126	NVjwVmluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M163c2lEPTB;OD64PVMyQSEQvF2=	MU\TRW5ITVJ?
Calu-6	NYj3[lJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rqOGlEPTB;OD65PVA1OiEQvF2=	NGLJdlFUSU6JRWK=
NCI-H23	MmLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTlwMUe3OFYh\|ryP	MnrhV2FPT0WU
WSU-NHL	M2LXO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLaRXlKSzVyPUmuO\|c1PzhizszN	M4K5SHNCVkeHUh?=
MMAC-SF	M2TKWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjYNJRjUUN3ME25Mlk4QTB2IN88US=>	Mk\TV2FPT0WU
SK-LMS-1	M4PlU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3Hqd2lEPTB;MUCuNlg{PCEQvF2=	M3XTOXNCVkeHUh?=
GCIY	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfHTWM2OD1zMD61PVI1KM7:TR?=	NYCyZ4JuW0GQR1XS
TE-15	MoGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTlTWM2OD1zMT62NFA1KM7:TR?=	NFTjSZlUSU6JRWK=
EoL-1-cell	NWHKfIpvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTFzLke2PFIh\|ryP	M3PlW3NCVkeHUh?=
NCI-H2081	MljQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPkTWM2OD1zMT63O\|g3KM7:TR?=	MYHTRW5ITVJ?
EW-3	M2\GcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDJTWM2OD1zMj6yOFY{KM7:TR?=	NUDoUlBKW0GQR1XS
CAS-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfUTWM2OD1zMj6zOlMyKM7:TR?=	NWfxOopkW0GQR1XS
C2BBe1	NYi0cWVlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnWTWM2OD1zMj62NVMyKM7:TR?=	NX3j[4lFW0GQR1XS
D-247MG	NHzpUWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2T4dmlEPTB;MUKuO\|k2OiEQvF2=	NHvMelRUSU6JRWK=
NCI-SNU-5	NWC5XplkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTF{LkiwNVMh\|ryP	MYrTRW5ITVJ?
LS-1034	NWrtWWszT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvvW4ZDUUN3ME2xOE4{QTd3IN88US=>	MlrtV2FPT0WU
EW-18	NXixN4s3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHQe292UUN3ME2xOE41PDhizszN	NWLhbFhDW0GQR1XS
Raji	NITpTIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIfX[IFKSzVyPUG0MlUxPDlizszN	MmT6V2FPT0WU
D-283MED	NV;3NotoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;R[opKUUN3ME2xOE43OjdzIN88US=>	NG\NNHRUSU6JRWK=
MZ2-MEL	Mo\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fPfmlEPTB;MUSuPVY6PiEQvF2=	MXPTRW5ITVJ?
NCI-SNU-16	M1e5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLKSIFKSzVyPUG1MlQ3OzNizszN	MoK3V2FPT0WU
P30-OHK	M3y0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlu4TWM2OD1zNz63PFMyKM7:TR?=	MUPTRW5ITVJ?
RXF393	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTF7LkCxPFYh\|ryP	NG\DU4pUSU6JRWK=
NCI-H1395	NInuNFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXZXWhxUUN3ME2yNE43PzB\|IN88US=>	NXzHdFdyW0GQR1XS
U-698-M	NIPNbpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV7JR\|UxRTJyLkewO\|Uh\|ryP	NFPOUVZUSU6JRWK=
NCI-SNU-1	M33Pdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHmS\|ViUUN3ME2yNE44OjJ\|IN88US=>	NFHJXYxUSU6JRWK=
SW684	NXW5N4pIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M32wfGlEPTB;MkGuNVcyPiEQvF2=	NUfNWHZEW0GQR1XS
NCI-H716	NYnzOldIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\0b2lEPTB;MkGuN\|E2PCEQvF2=	Ml;wV2FPT0WU
JVM-2	MmPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTJzLkSxN\|Mh\|ryP	NFy3[5JUSU6JRWK=
NCI-H1581	M4jMdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;6[nA3UUN3ME2yNk41OTR6IN88US=>	NIHFdJlUSU6JRWK=
CA46	Mn3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rLd2lEPTB;M{GuOlk{PiEQvF2=	NYnkbXNzW0GQR1XS
SNB75	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTN\|Lk[1NFMh\|ryP	NEHS[HNUSU6JRWK=
KNS-42	M1rlemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXnJR\|UxRTN3Lkm2NlQh\|ryP	NVryPGxHW0GQR1XS
TUR	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTN4LkC1NlEh\|ryP	MXTTRW5ITVJ?
REH	M4HIbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjOTWM2OD1\|Nz64NlEyKM7:TR?=	M{[5U3NCVkeHUh?=
EW-22	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3hTWM2OD12Mj6yPFg2KM7:TR?=	NWi3[JpwW0GQR1XS
NCI-H446	NG\OT2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTR{Lke4OVMh\|ryP	M17aUXNCVkeHUh?=
ES3	M1viUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jCTWlEPTB;NEOuNVM{QSEQvF2=	NH7uZXRUSU6JRWK=
EW-11	NImzPGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTR2LkiyNVgh\|ryP	M2D0dXNCVkeHUh?=
RH-1	M2\3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXLVI55UUN3ME20O{42QDF{IN88US=>	MlS0V2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	AcH3 / AcH4 / HDAC1 / HDAC2 / HDAC3; PubMed: 24203492 Pharm Res HCT-15 or fresh primary NK cells were treated with entinostat for 24 h, and AcH3, AcH4, and HDAC1, 2, and 3 were detected by Western blotting. Cleaved PARP; PubMed: 19148581 J Neurooncol Induction of PARP cleavage in Daoy cells upon exposure to MS-275 was demonstrated by Western blot analyses using antibodies that recognize the cleaved 89 kDa PARP protein. Pan-Actin (45 kDa) was used as a loading control. Caspase 8 ; PubMed: 19148581 J Neurooncol Cleavage of pro-Caspase-8 was demonstrated by Western blotting with extracts prepared from Daoy cells treated with 2.5 µM MS-275 for various time periods. Antibodies specific to human Caspase-8 or the loading control, pan-Actin were used to probe protein expression. DR4 / DR5; PubMed: 19148581 J Neurooncol Western blotting to detect DR4 and DR5 expression upon treatment of Daoy cells with 2.5 µM MS-275 for 4, 8 and 24 h. TopoIIα / TopoIIβ; PubMed: 21254166 Hepatology Upper panel, concentration-dependent effects of AR42, MS-275 and vorinostat on the expression of topoIIα versus topoIIβ after 48 h. Lower panel, time-dependent effect of 0.5 μM AR42 and 5 μM MS-275 on topoIIα versus topoIIβ expression in PLC-5 cells.	24203492 19148581 21254166
Immunofluorescence	phalloidin / snail; PubMed: 29855565 Sci Rep (C) Effect of MS-275 treatment on Snail expression and localization. MCs (mesothelial cells) were treated with MS-275 (250 nM), or DMSO for 48 hr and then stimulated with TGFβ1 (2 ng/ml) for 24 h before processing for immunofluorescence with a monoclonal antibody against Snail. Cell nuclei are shown in blue (Hoechst 33342). Confocal images are shown from one representative experiment of three performed. DR4 / DR5; PubMed: 19148581 J Neurooncol Flow Cytometry to measure cell surface expression of FAS, DR4 and DR5 using PE-labeled antibodies. Cells stained with isotype matched anti-human IgG antibodies served as controls. H3K4Me3 / H3K9Me3; PubMed: 22468166 Mol Cell Pharmacol Immunocytochemical analysis of the effects of AR42, SAHA, and MS-275 at the indicated concentrations on H3K4Me3 (upper panels) and H3K9Me3 (lower panels) after 24 h of treatment in LNCaP cells.	29855565 19148581 22468166
Growth inhibition assay	Cell proliferation; PubMed: 24203492 Pharm Res (A) HCT-15 cells were cultured in indicated concentrations of entinostat for up to 72 h, and proliferation determined by MTT assay as indicated. (B) HCT-15, CCH-OS-D, COL and HOS cells were cultured in indicated concentrations of entinostat for 72 h, and viable cell number was determined using the Vi-cell assay and proliferation index calculated. (C) Freshly-isolated human NK cells were cultured in indicated concentrations of entinostat for up to 72 h, and viability was assessed by flow cytometry for 7-AAD uptake. , P < 0.05, ; P ≤ 0.01; **, P ≤ 0.001 Cell viability; PubMed: 28969017 Oncotarget PANC-1, MIA PaCa-2, BxPC3, CFPAC-1, SUIT2 and SUIT2 Clone 1 cells were plated at a density of 3-5×103 per well in 96-well microtiter plates, allowed to adhere overnight and incubated for 72 hours in the presence of variable concentrations of entinostat (0-100μM). Cell viability was determined by XTT assays. The data presented are the mean values from triplicate wells from two independent experiments ±SE.	24203492 28969017
ELISA	GCP-2 / MCP-2 / MIF ; PubMed: 24241152 Molecules MS-275 and SAHA suppressed the secretion of GCP-2, MCP-2 and MIF in E11 cells. (A) GCP suppression. (B) MCP-2 suppression. (C) MIF suppression. E11 cells were incubated with HDAC inhibitors at various concentrations for 1 h before they were stimulated by LPS. 24 h later, the secretion of GCP-2, MCP-2 and MIF were quantified by ELISA (n = 8). Bars show the mean and SD in (A–C).	24241152

体内研究

MS-275按49 mg/kg剂量作用于除了HCT-15的人类移植瘤都显示出强抗癌活性。^[1]MS-275促进恶性实体瘤和恶性血液病的治疗可能性，及生理和畸变基因表达的调节。^[4]MS-275和IL-2联用，作用于肾细胞癌显示出强抗癌活性，因为降低调节性T细胞和增强脾细胞的表达。^[5]

激酶实验：^[6]	- 合并标准HDAC实验: 用HDAC buffer按1:6稀释鼠肝内的酶。重组人类HDACs按1:4稀释在HDAC buffer中。用于标准HDAC实验，60 μl HDAC buffer和10 μl 稀释的酶溶液在30^oC混合。在HDAC buffer中加入30 μl基底液开始HDAC反应，随后在30^oC下温育30分钟。加入100 μl胰蛋白酶溶液终止反应，胰蛋白酶溶液由溶于50 mM Tris-HCl（pH 为8.0）的10 mg/ml 胰蛋白酶, 100 mM NaCl,及 2 μM TSA组成。30^oC下温育20分钟，通过测定460纳米(λ_ex = 390 nm)处的荧光监测AMC的释放。使用释放的AMC校准荧光强度。用于标准时间过程实验，在初始100 μl HDAC 反应中加入20 pmol 基底物。2-50 pmol 基底物的酶法分析产物获得荧光AMC，通过测量这种荧光AMC来测定 K_m值和 V_max值。使用Hanes 图分析实验数据。记录的AMC信号是针对没有酶而有buffer和基底物的空白区。
细胞实验：^[2]	- 合并 Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St和HCT-15细胞 Concentrations: 10 μM 左右 Incubation Time: 3天 Method: 5×10³个肿瘤细胞接种到96孔板上，加入梯度浓度MS-275培养三天。细胞用0.1 mg/mL中性红在CO₂反应器中染色1小时，测定中性红与50 μL乙醇和150 μL 0.1 M Na₂HPO₄溶解后的OD540,测定IC50值。 (Only for Reference)
动物实验：^[1]	- 合并 Animal Models: 侧腹皮下注射A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1和Calu-3细胞的裸鼠 Dosages: 12.3, 24.5和49 mg/kg Administration: 每天口服处理一次，每周进行5天，持续4周。 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	75 mg/mL (199.25 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 2% DMSO+30% PEG 300+ddH2O	10mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Entinostat (MS-275) SDF

分子量	376.41
化学式	C₂₁H₂₀N₄O₃
CAS号	209783-80-2
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	SNDX-275

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03829930	Recruiting	Drug: Entinostat\|Drug: Enzalutamide	Prostate Adenocarcinoma	George Washington University	May 1 2019	Phase 1
NCT03765229	Recruiting	Drug: Entinostat\|Drug: Pembrolizumab	Melanoma	UNC Lineberger Comprehensive Cancer Center\|Syndax Pharmaceuticals Inc.	March 22 2019	Phase 2
NCT03473639	Recruiting	Drug: Entinostat\|Drug: Capecitabine	Metastatic Breast Cancer\|Breast Cancer	University of Virginia\|Syndax Pharmaceuticals	January 29 2019	Phase 1
NCT03361800	Active not recruiting	Drug: Entinostat	Breast Cancer\|Invasive Breast Cancer\|ER-Negative PR-Negative HER2-Negative Breast Cancer	UNC Lineberger Comprehensive Cancer Center\|Syndax Pharmaceuticals\|National Cancer Institute (NCI)	November 28 2018	Early Phase 1
NCT03192111	Completed	Drug: Entinostat	Renal Impairment\|Healthy Volunteer	Syndax Pharmaceuticals	July 27 2017	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
I would like to use Entinostat（Catalog No.S1053） for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?
回答：
2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

选择性强的HDAC抑制剂

RGFP966 : HDAC3-selective, IC50=80 nM.
选择性强的HDAC抑制剂

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
活性最高的HDAC抑制剂

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA批准的HDAC抑制剂

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
最新的HDAC抑制剂

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

研究领域

产品类型

Entinostat (MS-275)

客户使用Selleck生产的Entinostat (MS-275)发表文献282篇：

产品安全说明书

HDAC抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Entinostat (MS-275) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-05-15)

技术支持

常见问题及建议解决方法

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品